Analysis utilizing Oncomine indicated that RRM2 and KIF23 expression patterns are significantly associated with the initial treatment response, the methylation status of MGMT, and the recurrence status in glioblastoma, suggesting their potential as markers for treatment strategy and prognosis evaluation (Fig. 7). The gene discussed is RRM2; the disease is glioblastoma.